Rare Cancers Australia has released an updated 'counting the cost' report focused on achieving change through the current health technology assessment review but CEO Richard Vines has also called for greater transparency in the process. …
'We talk about the cost of action, but we need to think about the cost of inaction'
September 28, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Algorae signs two-part deal with Umedica to expand Australian portfolio
October 19, 2026 - - Latest News -
Novartis, Boehringer Ingelheim leaders join Medicines Australia board
October 19, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5. Ep.36
October 19, 2026 - - Podcast -
Cancer physicians now running communication skills workshops on how to discuss private pay
October 19, 2026 - - Latest News -
'If your doctor prescribes it, it should be covered,' pollster recommends as the key message
October 19, 2026 - - Latest News -
Global headwinds and new contenders set the agenda for Australia's 'Biggest Week in Biotech'
October 19, 2026 - - Latest News -
Mixed PBAC outcomes for multi-cancer immunotherapy listings
October 19, 2026 -